Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multiple Antigen Specific Cellular Therapy
- Development stage
- Unknown
- Lead developer
- HRYZ Biotech
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous, Subcutaneous, Intradermal
01
Overview
Multiple Antigen Specific Cellular Therapy (MASCT) is an autologous cellular immunotherapy developed by Beijing Hengrui Yuanzheng Biotechnology (HRYZ Biotech). The therapy utilizes a sequential administration of dendritic cells (DCs) and effector T cells. In the MASCT protocol, autologous DCs are pulsed with a panel of multiple tumor-associated antigens (TAAs) relevant to the specific cancer type, such as hepatocellular carcinoma (HCC). These antigens typically include Alpha-fetoprotein (AFP), Glypican-3 (GPC3), and various MAGE family proteins. The antigen-primed DCs are then used to stimulate and expand autologous T cells ex vivo or to prime the immune system in vivo. The goal of this multi-antigen approach is to induce a broad and robust polyclonal T-cell response, reducing the likelihood of tumor escape through antigen loss and effectively targeting residual disease following curative treatments like surgical resection.
- Other names
- MASCT-HCCMultiple Antigen-Specific Cellular Therapy
02
Targets
TUMAPs-MHC (Multiple tumor-associated antigen peptides presented by MHC on dendritic cells/tumor cells)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Multiple Antigen Specific Cellular Therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multiple Antigen Specific Cellular Therapy.